Baxalta Ventures logo

Baxalta Ventures

North America, Massachusetts, United States, Cambridge

Description

Baxalta Ventures is a biotech investment fund focused on novel therapeutics, medical technologies, and more.

Investor Profile

Baxalta Ventures has made 6 investments, with 0 in the past 12 months and 33% as lead.

Stage Focus

  • Series A (67%)
  • Series B (17%)
  • Series C (17%)

Country Focus

  • United States (83%)
  • The Netherlands (17%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Emergency Medicine
  • Pharmaceutical
  • Clinical Trials
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Baxalta Ventures frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 1
New Leaf Venture Partners
North America, New York, United States, New York
Co-Investments: 1
Kleiner Perkins
North America, California, United States, Menlo Park
Co-Investments: 1
Medicxi
Europe, England, United Kingdom, London
Co-Investments: 1
MPM Capital
North America, Massachusetts, United States, Boston
Co-Investments: 1
SR One
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 1
CI
North America, New York, United States, New York
Co-Investments: 1
Apple Tree Partners
North America, New York, United States, New York
Co-Investments: 4
Partners Innovation Fund
North America, Massachusetts, United States, Boston
Co-Investments: 4

What are some of recent deals done by Baxalta Ventures?

Syntimmune

Boston, Massachusetts, United States

Syntimmune develops differentiated drug candidates in a wide range of autoimmune diseases.

BiotechnologyEmergency MedicineHealth CareMedicalPharmaceutical
Series BJun 21, 2017
Amount Raised: $50,000,000
Syntimmune

Boston, Massachusetts, United States

Syntimmune develops differentiated drug candidates in a wide range of autoimmune diseases.

BiotechnologyEmergency MedicineHealth CareMedicalPharmaceutical
Series ANov 17, 2016
Amount Raised: $8,000,000
Gadeta

Utrecht, Utrecht, The Netherlands

Gadeta is a research and development company that develops immunotherapies for cancer.

BiotechnologyMedicalTherapeutics
Series AMar 29, 2016
Amount Raised: $7,902,452
Syntimmune

Boston, Massachusetts, United States

Syntimmune develops differentiated drug candidates in a wide range of autoimmune diseases.

BiotechnologyEmergency MedicineHealth CareMedicalPharmaceutical
Series AMar 22, 2016
Amount Raised: $10,000,000
True North Therapeutics

South San Francisco, California, United States

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases.

BiotechnologyClinical TrialsHealth Care
Series CDec 3, 2015
Amount Raised: $40,000,000
Syntimmune

Boston, Massachusetts, United States

Syntimmune develops differentiated drug candidates in a wide range of autoimmune diseases.

BiotechnologyEmergency MedicineHealth CareMedicalPharmaceutical
Series AOct 24, 2014
Amount Raised: $8,000,000